saphnelo
astrazeneca ab - anifrolumab - lupus erythematosus, szisztémás - immunszuppresszánsok - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - daganatellenes szerek - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - myeloma multiplex - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
eprex 1000 ne oldatos injekció előretöltött fecskendőben
janssen-cilag kft. - alfa-epoetin -
eprex 2000 ne oldatos injekció előretöltött fecskendőben
janssen-cilag kft. - alfa-epoetin -
eprex 10 000 ne oldatos injekció előretöltött fecskendőben
janssen-cilag kft. - alfa-epoetin -
eprex 3000 ne oldatos injekció előretöltött fecskendőben
janssen-cilag kft. - alfa-epoetin -
eprex 4000 ne oldatos injekció előretöltött fecskendőben
janssen-cilag kft. - alfa-epoetin -
maxipime 1 g por oldatos injekcióhoz
bristol-myers squibb kft. - cefepime -
maxipime 2 g por oldatos injekcióhoz
bristol-myers squibb kft. - cefepime -